Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Twin Acquisitions, China-wide Plasma Shortage, Boost Earnings For China Biologic

This article was originally published in PharmAsia News

Executive Summary

BEIJING - The leadership of China Biologic Products, the country's biggest privately held provider of plasma-based biopharmaceuticals, said that the acquisition of two competitors earlier this year helped elevate profits in the second quarter, and that the emergence of the A/H1N1 pandemic could bolster sales throughout the year

You may also be interested in...

Acquisitions Catapult China Biologic Into Leading Biopharma Outfit; Position It For Global Competition With U.S., EU Players

BEIJING - The chief executive officer of China Biologic Products Inc. said an aggressive acquisition strategy has helped transform the company into China's leading privately held provider of plasma-based biopharmaceuticals, and that the outfit is aiming to expand its geographical footprint across the globe

China’s SFDA To Require Electronic Tags For All Domestic Drugs; Imported Pharmaceuticals Likely To Follow

BEIJING - China's State FDA has issued a series of regulations in recent months that will ultimately require all pharmaceuticals, biologics and medical devices produced domestically to carry electronic tags with essential identifying information

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts